Osteoporosis Drugs Market - Forecast(2024 - 2030)

Osteoporosis Drugs Market size is valued at $15.3Bn by 2019, and is anticipated to grow at a CAGR of 5.2% during the forecast period 2020-2025. The Osteoporosis Drugs Market growth rate is attributed to severe fractures, which can have deleterious effects on the health of patient. The bones become porous in this medical condition, which makes them more fragile and, in turn, prone to factures, caused by the over production of the hormone parathyroid. Osteoporosis also occur owing to a number of diseases or treatments, which includes anorexia, alcoholism, kidney disease, hyperthyroidism, and surgical removal of the ovaries. Certain medications also help to increase the rate of bone loss, including some anti-seizure medications, proton pump inhibitors, chemotherapy, selective serotonin reuptake inhibitors, and glucocorticosteroids. From improvement’s made in the treatment and medication procedures like Parathyroid Hormone(PTH) treatment, Estrogen (Hormone Therapy) and the usage of various inhibitors like selective estrogen inhibitors modulator (SERM), RANK ligand (RANKL) Inhibitor, etc. to the chemical advancements made in reducing the side effects of the drugs along with the reduction in time-consumption for the drugs approval process is anticipated to propel the Osteoporosis Drugs Market during the forecast period 2020-2025.

 

The report: “Osteoporosis Drugs Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Osteoporosis Drugs Market: 

By Drugs Type: Antiresorptive Agents, Anabolic Agents. 

By Route of Administration: Oral, Injection/Intravenous Infusion and Others.

By Gender: Male, Female.

By Geography: North America, Europe, Asia-Pacific and RoW.

RANK ligand (RANKL) Inhibitor of Antiresorptive Agents segment held the largest share in the market and is poised to grow with a CAGR of 4.2% over Anabolic Agents as this inhibitor can be used in conjunction with other drugs to impart a synergistic effect in the overall treatment regime. As these inhibitors are used for the management of osteoporosis in patients at high risk for bone fractures so, there is high growth possibility achieved as a result of more number of positive patient’s results associated with rank ligand inhibitors. Furthermore, impacts like reduced cell bone turnover, increased bone mineral density, etc. are anticipated to boost the market growth in the forecast period of 2020-2025.

 

On the basis of Gender, female segment held the major share of the market in terms of revenue. The reason might be attributed to an upsurge in incidence as a result of menopause in women. According to a report published by International Osteoporosis Foundation, it states that nearly 30% of all the postmenopausal women have an increased rate of osteoporosis owing to low bone mass amongst 200 million people worldwide. Moreover, according to National Institutes of Health Osteoporosis and Related Bone Diseases, lifestyle associated factors such as alcohol abuse, sedentary lifestyle, smoking is found to promote this condition in female than in male. Osteoporosis Drugs sales is believed to rise effectively as the aforementioned factor poses the high clinical urgency to curb osteoporosis is anticipated to further expand the consumption rate over the projection period of 2020-2025. 

North America dominated the Osteoporosis Drugs Market with a share of 37% in 2019. North America remains the largest consumer of Osteoporosis Drugs owing to the high prevalence of osteoporosis patients in the region, established healthcare infrastructure, availability of branded drugs coupled with the presence of key players which continues to expand its market. High initial capital investment on R&D investing in drug discovery and development and increasing healthcare expenditure, beneficial government initiatives along with increasing number of research partnerships with key players are to cater the Osteoporosis Drugs Market in the forecast period of 2020-2025. According to a report published by the National Institute of Health in 2018, approximately 53 million individuals in US either suffer from osteoporosis or at an increased risk owing to low bone mass which leads to an increase in the patient’s base for osteoporosis diseases which ensures the Osteoporosis Drugs Market growth.

With rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that results in bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc. there has been an increase in the number of osteoporosis patients worldwide which can be considered as a Osteoporosis Drugs key driver of the market during the forecast period 2020-2025. 

The major challenge for the market is the poor efficacy and side effects of present therapies, loss of patents life owing to non-life threatening nature and poor symptoms of osteoporosis, etc. The stringent rules and regulations by the government along with the time-consumption for the drugs approval process is the major problem for some of the regions in Asia-Pacific. 

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Osteoporosis Drugs Market. In 2019, Osteoporosis Drugs Market share is fragmented by the top ten players present in the market. Osteoporosis Drugs Market top 10 companies are Merck & Co. Inc., Radius Health Inc., Novartis AG, Eli Lilly and Company, Pfizer Inc., Amgen Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., UCB S.A., Teva Pharmaceutical Industries Ltd. and others.